-1.svg "Close Icon (3)-1")
.svg "Close Icon (3)")
- Share
-
In a recent Hospital and Healthcare article, HeraMED CEO and co-founder David Groberman discusses the ASX-listed company’s innovative take-home device for parents to monitor their baby’s heartrate in utero and share the data seamlessly with their doctor or midwife.
The HeraBEAT device is designed to have the same level of accuracy as the professional machines used in hospitals and includes an extensive telehealth capability to significantly reduce the number of times a pregnant person has to visit a hospital or clinic over the course of their pregnancy.
During the pandemic there has been a significant rise in telehealth services and the article delves into how medical technology companies like HeraMED are ‘redesigning current models of care’, specifically in the way doctors, nurses and patients interact.
‘We’ve seen that coupling telehealth with tech innovation can lead to better outcomes for patients… with potential to deliver significant positive outcomes and cost effectiveness for both the pregnant person and their hospital,’ Mr Groberman said.
Read more here: How technology is changing maternity care – Hospital and Healthcare
If you’d like to discuss your strategic communication call us or contact us here.
